ReviewMolecular biomedicine2026
Autism: epidemiology, genetics, molecular mechanisms, clinical features, diagnosis, and management.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition characterized by persistent deficits in social communication and restricted, repetitive behaviors. Global prevalence has risen steadily, yet reported rates vary markedly across regions and populations. These discrepancies reflect inequities in diagnostic access and screening capacity rather than true differences in incidence. This review integrates recent advances across the full ASD research spectrum. We first examine global epidemiological patterns and demographic disparities. We then dissect the genetic architecture of ASD, including rare and common variants, copy number variations, and gene-environment interactions that disrupt prenatal and early postnatal brain development. At the molecular level, diverse risk factors converge on shared neurodevelopmental mechanisms. These include synaptic dysfunction, dysregulated signaling through mTOR, Ras-ERK-MAPK, Wnt and Notch pathways, impaired neurogenesis, chronic neuroimmune inflammation, and excitatory-inhibitory imbalance. We also discuss how these mechanisms manifest in core clinical features, including social deficits, repetitive behaviors, and sensory abnormalities. We summarize current diagnostic standards and their limitations. Cross-species animal models, from Drosophila to non-human primates, are evaluated for their essential roles in mechanistic validation and therapeutic screening. Finally, we assess clinical management strategies, ranging from behavioral and educational interventions to pharmacological and supportive services. By tracing a continuous path from risk factors at the population level through molecular pathophysiology to interventions guided by mechanism, this review offers an integrative synthesis that connects basic discovery to clinical translation. We further discuss how multi-omics and artificial intelligence may advance precise diagnosis rooted in mechanism and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.